These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19791797)

  • 1. Role of E166 in the imine to enamine tautomerization of the clinical beta-lactamase inhibitor sulbactam.
    Kalp M; Buynak JD; Carey PR
    Biochemistry; 2009 Nov; 48(43):10196-8. PubMed ID: 19791797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detecting a quasi-stable imine species on the reaction pathway of SHV-1 β-lactamase and 6β-(hydroxymethyl)penicillanic acid sulfone.
    Che T; Rodkey EA; Bethel CR; Shanmugam S; Ding Z; Pusztai-Carey M; Nottingham M; Chai W; Buynak JD; Bonomo RA; van den Akker F; Carey PR
    Biochemistry; 2015 Jan; 54(3):734-43. PubMed ID: 25536850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase.
    Totir MA; Helfand MS; Carey MP; Sheri A; Buynak JD; Bonomo RA; Carey PR
    Biochemistry; 2007 Aug; 46(31):8980-7. PubMed ID: 17630699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.
    Kalp M; Totir MA; Buynak JD; Carey PR
    J Am Chem Soc; 2009 Feb; 131(6):2338-47. PubMed ID: 19161282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theoretical investigation on reaction of sulbactam with wild-type SHV-1 β-lactamase: acylation, tautomerization, and deacylation.
    Li R; Liao JM; Gu CR; Wang YT; Chen CL
    J Phys Chem B; 2011 Sep; 115(34):10298-310. PubMed ID: 21797222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.
    Helfand MS; Totir MA; Carey MP; Hujer AM; Bonomo RA; Carey PR
    Biochemistry; 2003 Nov; 42(46):13386-92. PubMed ID: 14621983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta-lactamase: Raman crystallographic evidence.
    Totir MA; Cha J; Ishiwata A; Wang B; Sheri A; Anderson VE; Buynak J; Mobashery S; Carey PR
    Biochemistry; 2008 Apr; 47(13):4094-101. PubMed ID: 18324783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computer modeling on the tautomerization of sulbactam intermediate in SHV-1 β-lactamases: E166A mutant vs. wild type.
    Li R; Wang YT; Chen CL
    J Mol Graph Model; 2013 Mar; 40():131-9. PubMed ID: 23395858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.
    Totir MA; Padayatti PS; Helfand MS; Carey MP; Bonomo RA; Carey PR; van den Akker F
    Biochemistry; 2006 Oct; 45(39):11895-904. PubMed ID: 17002290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.
    Padayatti PS; Helfand MS; Totir MA; Carey MP; Carey PR; Bonomo RA; van den Akker F
    J Biol Chem; 2005 Oct; 280(41):34900-7. PubMed ID: 16055923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why the extended-spectrum beta-lactamases SHV-2 and SHV-5 are "hypersusceptible" to mechanism-based inhibitors.
    Kalp M; Bethel CR; Bonomo RA; Carey PR
    Biochemistry; 2009 Oct; 48(41):9912-20. PubMed ID: 19736945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why tazobactam and sulbactam have different intermediates population with SHV-1 β-lactamase: a molecular dynamics study.
    Li R; Wang YT; Chen CL
    J Mol Model; 2013 Jun; 19(6):2519-24. PubMed ID: 23455927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
    Papp-Wallace KM; Bethel CR; Distler AM; Kasuboski C; Taracila M; Bonomo RA
    Antimicrob Agents Chemother; 2010 Feb; 54(2):890-7. PubMed ID: 20008772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
    Helfand MS; Taracila MA; Totir MA; Bonomo RA; Buynak JD; van den Akker F; Carey PR
    Biochemistry; 2007 Jul; 46(29):8689-99. PubMed ID: 17595114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Conformations of Acylation Adducts of Inhibitors of β-Lactamase from Mycobacterium tuberculosis.
    Tassoni R; Blok A; Pannu NS; Ubbink M
    Biochemistry; 2019 Feb; 58(7):997-1009. PubMed ID: 30632739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interplay between the Enamine and Imine Forms of the Hydrolyzed Imipenem in the Active Sites of Metallo-β-lactamases and in Water Solution.
    Krivitskaya AV; Khrenova MG
    J Chem Inf Model; 2022 Dec; 62(24):6519-6529. PubMed ID: 35758922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone.
    Padayatti PS; Sheri A; Totir MA; Helfand MS; Carey MP; Anderson VE; Carey PR; Bethel CR; Bonomo RA; Buynak JD; van den Akker F
    J Am Chem Soc; 2006 Oct; 128(40):13235-42. PubMed ID: 17017804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A structure-based analysis of the inhibition of class A beta-lactamases by sulbactam.
    Imtiaz U; Billings EM; Knox JR; Mobashery S
    Biochemistry; 1994 May; 33(19):5728-38. PubMed ID: 8180199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Insight into the Mechanism of Inhibitor Resistance in CTX-M-199, a CTX-M-64 Variant Carrying the S
    Cheng Q; Xu C; Chai J; Zhang R; Wai Chi Chan E; Chen S
    ACS Infect Dis; 2020 Apr; 6(4):577-587. PubMed ID: 31709791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors.
    Therrien C; Kotra LP; Sanschagrin F; Mobashery S; Levesque RC
    FEBS Lett; 2000 Mar; 470(3):285-92. PubMed ID: 10745083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.